Summary

• Sava announced a $36 million Series B led by Ascensia on 9 October.
• Ascensia agreed to initial exclusive European commercialisation and distribution, conditional on product readiness.
• Sava targets CE approval for non-adjunctive use and commercialisation in 18–24 months; approval is not granted.

London health technology company Sava has raised $36 million in Series B financing and agreed a European commercialisation partnership with Ascensia Diabetes Care for its investigational glucose microsensor. The financing and agreement were announced on 9 October, but the device has not yet obtained the regulatory approval required for commercial launch.

Ascensia, a subsidiary of PHC Group, led the round. Sava also named Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments and Pentland Ventures among participating investors. The latest financing brings the company’s reported total funding to $68 million and is intended to support manufacturing scale-up and preparations for a pivotal clinical study.

The partnership includes an initially exclusive European commercialisation and distribution arrangement. That gives Sava an established prospective route to market, but it does not mean devices are already being sold through Ascensia. The company says commercialisation and CE approval for non-adjunctive use are targets for the next 18 to 24 months.

Sava was founded in 2019 and is based in London. Its wearable uses tiny sensing structures that penetrate just beneath the skin to measure substances in interstitial fluid. Sava describes the approach as painless and says its microsensors are around ten times shorter than the filament used in conventional continuous glucose monitors. Those are developer descriptions that require assessment in clinical and usability evidence.

The distinction between minimally invasive and non-invasive sensing is important. Sava’s technology still makes contact beneath the skin, even though its design aims to reduce disruption. It is also initially focused on glucose rather than a proven commercial system capable of monitoring every biomarker that the company hopes its broader platform could eventually support.

Continuous glucose monitors help users see changes in glucose over time, but accuracy depends on performance across the relevant concentration range and during everyday use. For people making insulin dosing decisions, reliable readings are especially consequential. Sava is targeting non-adjunctive approval, under which readings could support treatment decisions without routine confirmation by finger-prick measurement.

That approval has not been granted. The company says a pivotal clinical study is planned for 2026, and its own announcement identifies the sensor as experimental. It explicitly states that performance attributes have not been fully determined and that the device has not received approval from the UK MHRA or US FDA. The targeted European CE outcome must therefore remain prospective.

Sava has released early technical and clinical findings, but those should not be extrapolated into demonstrated performance across the population or circumstances relevant to a commercial indication. Pivotal evaluation will need to assess the actual device, comparison methods, reliability and duration of use under the proposed intended conditions.

Manufacturing presents a separate obstacle. Sava says the product was designed with high-volume production in mind, yet design intent differs from validated factory throughput and consistent yields. Financing can enable equipment, quality systems and production preparation; it does not establish that commercial volumes or costs have already been achieved.

The company says it intends to begin its pivotal study in 2026, rather than announcing that the study has been completed. Its microsensors are described as about ten times shorter than traditional CGM filaments, but reduced length by itself cannot establish equal accuracy, user comfort or durability. Those outcomes must be determined under the particular conditions of testing. A proposed wider biomarker platform is also separate from the first intended glucose product.

The concurrent financing and distribution components are confirmed from both sides of the agreement, including Ascensia’s parent PHC Group. The partnership is initially exclusive for Europe, not a statement that worldwide rights or regulatory clearances have been transferred. Nor does Ascensia’s established international customer footprint amount to a confirmed number of future Sava customers. The agreement supplies a prospective sales channel conditional on the device reaching the required development milestones.

Ascensia brings experience in glucose monitoring and existing healthcare distribution networks. Its products are sold in more than 90 countries, according to the partners, although the Sava agreement initially concerns Europe. The earliest decisive milestones are completion of the planned clinical study, evidence suitable for regulators and manufacturing readiness. Only after those steps can the announced distribution arrangement support an approved product launch.